期刊文献+

舒利迭联合无创通气治疗COPD合并Ⅱ型呼吸衰竭的疗效观察 被引量:16

暂未订购
导出
摘要 目的探讨舒利迭联合双水平气道正压通气(BiPAP)治疗COPD合并Ⅱ型呼吸衰竭的疗效。方法将48例COPD合并Ⅱ型呼吸衰竭患者随机分为2组,在常规抗感染、平喘基础上,2组均给予无创呼吸机辅助呼吸,每天早晚共8 h,观察组同时予舒利迭(50μg/500μg剂型,1吸,每日2次)吸入;观察2组患者治疗72 h后动脉血气分析的变化及治疗12周后肺功能的变化。结果治疗72 h后观察组患者的p(O2)、p(CO2)、pH及治疗12周后患者的肺功能均较治疗前明显改善,且比对照组改善明显。结论舒利迭联合BiPAP治疗老年COPD并Ⅱ型呼吸衰竭疗效好。
作者 钟莹
出处 《现代中西医结合杂志》 CAS 2012年第4期377-378,共2页 Modern Journal of Integrated Traditional Chinese and Western Medicine
  • 相关文献

参考文献5

二级参考文献19

  • 1方宗君,蔡映云.慢性支气管炎缓解期患者生命质量评估[J].中国行为医学杂志,1993,2(1):28-31. 被引量:25
  • 2彭敏,蔡柏蔷.美国胸科协会和欧洲呼吸协会对慢性阻塞性肺疾病诊治指南的修订[J].中华内科杂志,2005,44(5):394-397. 被引量:253
  • 3有创-无创序贯机械通气多中心研究协作组.以肺部感染控制窗为切换点行有创与无创序贯机械通气治疗慢性阻塞性肺疾病所致严重呼吸衰竭的随机对照研究[J].中华结核和呼吸杂志,2006,29(1):14-18. 被引量:280
  • 4朱蕾 钮善福.如何正确理解双气道正压通气[J].中华结核和呼吸杂志,1998,10:292-292.
  • 5Gugatt HG, Berman LB, Townsend M, et al. A measure of quality of life clinical trials in chronic lung disease. Thorax, 1987, 42 (2):773 - 778.
  • 6Cazzda M, Lorenzo GD, Pema FD, et al. Additive effects of salmeterol and fluticasone or theophyllinc in COPD. Chest, 2000,118(6) :1576 - 1581.
  • 7Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease:a randomized controlled trial. Lancet, 2003, 361 ( 9356 ) : 449 -456.
  • 8GOLD Executive Committee[DB/OL].Guidelines:Global Strategy for Diagnosis,Management,and Prevention of COPD,November 2006[2006-11-18].http://www.goldcopd.com/Guidelineitem.asp? l1 =2-12 = 1&intId =989.
  • 9Celli BR,MacNee W,Committee members.Standard for the diagnosis and treatment of patients with COPD:a summary of the ATS/ERS position paper.Eur Respir J,2004,23:932-946.
  • 10Celli BR,Cote CG,Marin JM,ct al.The body mass index,airflow obstruction,dyspnea and exercise capacity index in chronic obstructive pulmonary disease.N Engl J Med,2004,350:1005-1012.

共引文献8250

同被引文献108

  • 1彭敏,蔡柏蔷.美国胸科协会和欧洲呼吸协会对慢性阻塞性肺疾病诊治指南的修订[J].中华内科杂志,2005,44(5):394-397. 被引量:253
  • 2慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17. 被引量:8237
  • 3慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华内科杂志,2007,46(3):254-261. 被引量:1797
  • 4Chatterjee A, Shah M, D'Souza AO, et al.Observational study on the impact of initiating tiotropium alone versus tiotropium with fluticasone propionate/salmeterol combination therapy on outcomes and costs in chronic obstructive pulmonary disease[J].Respir Res,2012,17 ( 13 ) : 15.
  • 5Bjerg A,Lotvall J,Lundback B,et al.Differences in disease severity between users of symbicort and seretide(advair)in a Swedish population[J],Am J Respir Crit Care Med,2014,189:A1314.
  • 6Luk6csovits J,Nava S.Inspiratory pressure during noninvasive ventilation in stable COPD:help the lungs,but do not forget the heart[J].Eur Res J,2013,41(3):765-766.
  • 7Ekkernkamp E,Storre JH.Windisch W,et al.Impact of intelligent volume-assured pressure support on sleep quality in stable hypercapiiic chronic obstructive pulmonary disease patients:a randomized,crossover study[J].Respiration,2013,88(4):270-276.
  • 8Stone IS,Barnes NC,Petersen SE.Chronic obstructive pulmonary disease:a modifiable risk factor for cardiovascular disease[J].Heart,2012,98(14):1055-1062.
  • 9Lomas D.Lipson D,Miller BE.et al.An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease[J].J Clin Pharmacol,2012,52(3):416-424.
  • 10Javier Nannini L,Lasserson TJ,Poole P.Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease[J].Cochrane Database of Systematic Reviews,2012,9:CD006829.

引证文献16

二级引证文献98

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部